By Joe Hoppe

 

Hutchmed (China) Ltd. said Friday that its pancreatic neuroendocrine tumor treatment, surufatinib, has been granted approval for drug registration by the National Medical Products Administration of China.

The biopharmaceutical company said that surufatinib was previously approved by China for the treatment of nonpancreatic neuroendocrine tumors in December. The drug is marketed under the brand name Sulanda in China.

Shares at 1525 GMT were up 31.0 pence, or 8.0%, at 417.0 pence.

 

Write to Joe Hoppe at joseph.hoppe@wsj.com

 

(END) Dow Jones Newswires

June 18, 2021 11:49 ET (15:49 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more HUTCHMED China Charts.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more HUTCHMED China Charts.